trending Market Intelligence /marketintelligence/en/news-insights/trending/0oCStOLK2lSeSSDY56rVZQ2 content esgSubNav
In This List

Kobayashi Pharmaceutical fiscal Q4 profit falls YOY

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

451 Research Podcast

Next in Tech | Episode 42: AI/ML Infrastructure

Blog

Automating Credit Risk Surveillance Using Statistical Models

Case Study

Searching for Alpha with Textual Data


Kobayashi Pharmaceutical fiscal Q4 profit falls YOY

4237919 said its normalized net income for the fiscal fourth quarter ended March 31 amounted to ¥23.74 per share, a decrease from ¥24.88 per share in the year-earlier period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was ¥1.93 billion, a decline of 5.1% from ¥2.04 billion in the prior-year period.

The normalized profit margin fell to 6.2% from 6.5% in the year-earlier period.

Total revenue decreased on an annual basis to ¥31.19 billion from ¥31.57 billion, and total operating expenses declined on an annual basis to ¥28.22 billion from ¥28.51 billion.

Reported net income decreased 13.7% from the prior-year period to ¥1.78 billion, or ¥21.81 per share, from ¥2.06 billion, or ¥25.13 per share.

For the year, the company's normalized net income totaled ¥144.49 per share, compared with ¥143.25 per share in the prior year.

Normalized net income was ¥11.78 billion, compared with ¥11.73 billion in the prior year.

Full-year total revenue totaled ¥128.34 billion, compared with ¥127.29 billion in the prior year, and total operating expenses grew on an annual basis to ¥110.43 billion from ¥109.17 billion.

The company said reported net income rose on an annual basis to ¥12.45 billion, or ¥152.72 per share, in the full year, from ¥12.31 billion, or ¥150.28 per share.

s of June 26, US$1 was equivalent to ¥123.96.Kobayashi Pharmaceutical Co. Ltd.

4237919 said its normalized net income for the fiscal fourth quarter ended March 31 amounted to ¥23.74 per share, a decrease from ¥24.88 per share in the year-earlier period.